RxDoctor Payments Data

Abdulrahman Morad, MD

Cardiovascular Disease · Kansas City, KSNPI 1619288263

Payments from drug & device makers

$4,061in general payments, 2019–2025

Across 127 payments — averaging $31.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AOP Health US, LLC$2K
  • Amgen$858
  • Novo Nordisk$227
  • E.r. Squibb & Sons, L.L.C.$206
  • Pfizer$152
  • AstraZeneca$148
  • plus $872 from 16 others

What the payments were for

  • Food & beverage$4,02999%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,061 in reported general payments places this provider in the 60th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$155,822
Medicare patients
4,475
Services billed
6,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab139$159,048
EliquisApixaban99$109,918
Praluent PenAlirocumab86$75,734
JardianceEmpagliflozin38$57,011
VascepaIcosapent Ethyl46$28,758
OzempicSemaglutide22$27,461
FarxigaDapagliflozin Propanediol24$23,019
Icosapent Ethyl31$11,322
Ezetimibe386$9,606
Rosuvastatin Calcium427$5,876
Metoprolol Succinate226$3,231
Atorvastatin Calcium320$2,264
Losartan Potassium203$1,716
Carvedilol191$1,503
Amlodipine Besylate260$1,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$109,91899 claims
Boehringer IngelheimJardiance$72$57,01138 claims
Novo NordiskOzempic$227$27,46122 claims
AstraZenecaFarxiga$148$23,01924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →